Status:
COMPLETED
Comparison Study of Letrozole Alone or Letrozole With Zoledronic Acid in Early Breast Cancer, Neoadjuvant Therapy
Lead Sponsor:
Novartis
Conditions:
Breast Cancer
Eligibility:
FEMALE
65+ years
Phase:
PHASE2
Brief Summary
This study is to measure the extent of tumor shrinkage when Letrozole and Zoledronic Acid are given before surgery to newly diagnosed post-menopausal women with early breast cancer
Eligibility Criteria
Inclusion
- Inclusion Criteria
- Postmenopausal women
- Newly diagnosed with non metastatic breast cancer
- Candidate for mastectomy or breast-conserving surgery
- Exclusion Criteria
- Patients with invasive tumors
- Patients receiving anti-cancer treatment
- Patients who have undergone surgery
- Other protocol-defined exclusion criteria may apply.
Exclusion
Key Trial Info
Start Date :
September 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
190 Patients enrolled
Trial Details
Trial ID
NCT00247650
Start Date
September 1 2005
Last Update
March 1 2017
Active Locations (10)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Investigative Site
Edmonton, Alberta, Canada
2
Novartis Investigative Site
Vancouver, British Columbia, Canada
3
Novartis Investigative Site
Victoria, British Columbia, Canada
4
Novartis Investigative Site
London, Ontario, Canada